Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoceranib + Paclitaxel in Gastric/GEJ Cancer
NCT03707028Phase 2Terminated
- Sponsor
- Elevar Therapeutics
- Start
- Oct 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Elevar Therapeutics. Started Oct 2018; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03707028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707028.